Abivax
ABVX
302 hedge funds and large institutions have $7.18B invested in Abivax in 2026 Q2 according to their latest regulatory filings, with 91 funds opening new positions, 97 increasing their positions, 101 reducing their positions, and 40 closing their positions.
128% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 40
83% more call options, than puts
Call options by funds: $1.11B | Put options by funds: $606M
32% more funds holding in top 10
Funds holding in top 10: 28 → 37 (+9)
30% more capital invested
Capital invested by funds: $5.53B → $7.18B (+$1.65B)
19% more funds holding
Funds holding: 254 → 302 (+48)
5.67% more ownership
Funds ownership: 63.2% → 68.88% (+5.7%)
4% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 101
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
Helikon Investments
London,
United Kingdom
|
+$201M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$128M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$101M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$96.1M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$76.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$306M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$124M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$97.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$95.7M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$86M |
ABVX Hedge Fund Activity: Q2 2026 in Review
302 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q2 2026, worth a combined $7.18B — up 30% from $5.53B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new ABVX positions and 40 closed out — a net gain of 51 holders — while 97 added to existing stakes and 101 trimmed.
The largest buyer was Helikon Investments, adding an estimated $201M. The largest seller was UBS Group, cutting an estimated $306M.
- 302 institutional investors held Abivax (ABVX) as of Q2 2026, up from 254 in Q1 2026.
- Funds reported $7.18B of Abivax stock for Q2 2026, up 30% quarter-over-quarter.
- 91 funds opened new Abivax positions in Q2 2026 and 40 closed out, a net change of +51 holders.
- The largest Abivax buyer in Q2 2026 was Helikon Investments, an estimated $201M added.
- The largest Abivax seller in Q2 2026 was UBS Group, an estimated $306M sold.
Based on aggregated 13F filings for Q2 2026.